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Introduction
Alzheimer’s disease (AD) is the leading cause of dementia 
worldwide and is the sixth leading cause of death in the United 
States (1). The histopathological hallmarks of AD are extracellu-
lar amyloid plaques composed predominantly of the amyloid-β 
(Aβ) peptide and neurofibrillary tangles (NFTs) within neurons 
consisting of abnormally aggregated, hyperphosphorylated tau 
protein (for reviews, refs. 2–4). Beyond tau and Aβ pathologies, 
neuroinflammatory changes are present in AD and in primary 
tauopathies (5), including alterations in the morphology, reac-
tivity, distribution, and gene expression of microglia. The gene 
expression changes that occur in microglia in the presence of 
amyloid, tau, and other pathologies have been termed by some 
as disease-associated microglia (DAM) (6) or the microglial neu-
rodegenerative (MGnD) phenotype (7). In the DAM and MGnD 
phenotypes, there is a downregulation of so-called homeostat-
ic microglial genes such as P2ry12, Tmem119, and Cx3cr1, while 
there is an increase in the expression of several other genes such 
as Apoe, Tyrobp, and Trem2 (6, 7). However, the exact contribu-
tions of innate immune activation to different types of patholo-
gies and neurodegeneration are still not clear.
In the last decade, several novel genetic factors linked with 
increased risk of AD have been identified thanks to new whole- 
genome sequencing and genome-wide association studies 
(GWAS). Interestingly, many of these genetic risk factors 
encode proteins involved in microglial function and inflamma-
tion including triggering receptor expressed on myeloid cells 2 
(TREM2), CD33, CR1, ABCA7, SPI1, and SHIP1 (8). Particular 
interest has been given to the microglia-expressed TREM2, 
since rare variants in the TREM2 gene increase AD risk 2- to 
4-fold (9, 10). TREM2 is a receptor that belongs to the immu-
noglobulin superfamily and is expressed on myeloid cells such 
as microglia in the brain (11, 12). TREM2 signaling is associat-
ed with a number of downstream cellular processes including 
proliferation and survival, suppression of Toll-like receptor–
induced inflammatory cytokine production, and facilitation of 
metabolic ATP production (13). Several TREM2 variants have 
been shown to impair, but not block, functional TREM2 signal-
ing, resulting in the partial loss of function of the receptor. The 
most common AD-associated TREM2 variant is rs75932628, 
a single-nucleotide polymorphism encoding an arginine-to- 
histidine missense substitution at amino acid 47 (R47H) 
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signaling in the context of tauopathy and its associated neuro-
degeneration. Therefore, we investigated the impact of the most 
prominent AD-associated TREM2 variant (R47H) on tau pathol-
ogy and tau-mediated brain damage in the PS19 mouse mod-
el of tauopathy. PS19 mice were crossed with mice expressing 
human TREM2 common variant, TREM2CV (PS19-T2CV mice), or 
human TREM2R47H lacking the endogenous murine Trem2 gene 
(PS19-T2R47H mice). We hypothesized that TREM2R47H would 
result in a decreased microglial inflammatory response and would 
protect against tau-dependent neurodegeneration. We observed 
that PS19-T2R47H mice have reduced p-tau staining compared 
with PS19-T2CV mice. Moreover, PS19-T2R47H mice have signifi-
cantly attenuated brain atrophy and synapse loss compared with 
PS19-T2CV mice. Gene expression analyses and CD68 immunos-
taining revealed attenuated microglial reactivity in PS19-T2R47H 
versus PS19-T2CV mice. Importantly, a decrease in phagocytosis 
of postsynaptic elements by microglia expressing TREM2R47H was 
detected in PS19 mice and in postmortem human AD brains. Col-
lectively, these findings suggest that reduced TREM2 signaling 
reduces microglial conversion to a more proinflammatory, phago-
cytic state and is protective against neurodegeneration in the set-
ting of advanced tauopathy.
Results
Effects of TREM2R47H on p-tau pathology. To determine whether 
the presence of the R47H variant of TREM2 affects tau patholo-
gy and tau-related inflammation and neurodegeneration, we used 
the PS19 tauopathy mouse model that overexpresses 1N4R hTau 
containing the P301S mutation that causes a familial form of fron-
tal temporal dementia. By 9 months of age, this model develops 
strong tau hyperphosphorylation and aggregation, neurofibrillary 
tangle deposition, and gliosis, as well as neuronal loss, brain atro-
phy, and loss of synaptic proteins in specific brain regions includ-
ing the hippocampus, entorhinal cortex, piriform cortex, and 
amygdala (28, 29). We crossed PS19 mice on a mouse TREM2-KO 
background with bacterial artificial chromosome (BAC) trans-
genic mouse lines expressing either human TREM2CV or the AD- 
associated human variant TREM2R47H on a mouse TREM2-KO 
background (15). Importantly, TREM2CV and TREM2R47H mice 
express a similar level of TREM2 protein in the brain and expres-
sion of TREM2CV, but not TREM2R47H, rescues TREM2-dependent 
phenotypes such as plaque-associated microgliosis (15).
At 3 months of age, before the overt onset of tau pathology, we 
observed reduced staining with an antibody (AT8) specific for p-tau 
phosphorylated on serine 202 and threonine 205 (p.Ser202/p.
Thr205), in the hippocampus (Supplemental Figure 1, B and D; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI138179DS1) and piriform cortex (Supplemen-
tal Figure 1, A and C) of PS19-T2R47H mice compared with PS19-
T2CV mice, although the change was only statistically significant in 
the hippocampus. Staining with antibodies AT180 (p.Thr231) and 
PG5 (p.Ser409) did not reveal any significant differences in p-tau 
between PS19-T2R47H mice and PS19-T2CV mice in the piriform 
cortex (Supplemental Figure 1, E, G, I, and K) or hippocampus 
(Supplemental Figure 1, F, H, J, and L). To further examine tau and 
p-tau levels in these mice, we performed a biochemical extraction 
of hippocampal brain tissue and measured the concentration of 
(9, 10). The TREM2R47H variant results in decreased TREM2 sig-
naling upon ligand-induced stimulation (14, 15).
In order to better understand the role of TREM2 and AD- 
associated TREM2 variants in AD pathogenesis, several studies 
have used models of AD pathology. In vivo studies in mouse mod-
els of amyloid deposition indicate a critical function for TREM2 
in the clustering of microglia around plaques, plaque compac-
tion, microglial proliferation, and phagocytosis, and in decreas-
ing Aβ-induced neuritic dystrophy and tau seeding/spreading. 
TREM2 knockout or expression of the TREM2R47H variant have 
been shown to affect these phenotypes in the opposite direction 
(14–18). These studies suggest that TREM2 signaling is protective 
in decreasing Aβ-mediated local injury and in exacerbating the 
Aβ-induced spreading of tau pathology. However, in AD and in 
primary tauopathies, the accumulation of aggregated, hyperphos-
phorylated tau, and not Aβ, strongly correlates with local brain 
atrophy and neuronal death. In AD, the accumulation of patho-
logical forms of tau in the neocortex associated with atrophy and 
cell death does not begin to occur until about 15–25 years after the 
onset of Aβ deposition (19). The role of TREM2 and TREM2 vari-
ants linked to AD in the setting of tauopathy has been much less 
studied. However, numerous clues in the literature suggest a link 
between tau pathology and TREM2 in AD. In the cerebrospinal 
fluid (CSF) of AD patients, soluble TREM2 has been shown to cor-
relate with total and phosphorylated tau (p-tau, Thr181) levels (20, 
21). Moreover, AD patients harboring the R47H variant of TREM2 
display higher levels of both total tau and p-tau (Thr181) in CSF 
compared with noncarriers (22, 23). Importantly, levels of p-tau in 
the CSF correlate with tau pathology burden in the brain and with 
neuronal loss and cognitive decline in AD patients (24). Previous-
ly, we reported a decrease in brain atrophy as well as attenuated 
microgliosis in the brains of PS19 mice lacking TREM2 without a 
significant change in tau pathology (25). In another study, Sayed 
et al. also found that TREM2 knockout protected against tau- 
mediated microglial reactivity and atrophy (25), but that TREM2 
haploinsufficiency was associated with elevated expression of 
proinflammatory markers, exacerbated atrophy, and increased 
tau pathology in PS19 mice (26). Finally, Bemiller et al. crossed 
TREM2 knockout mice with mice expressing human tau (hTau 
mice), a less aggressive mouse model of tauopathy, and identified 
a decrease in microgliosis in TREM2-deficient hTau mice (27), as 
observed in TREM2-deficient PS19 mice, but reported that com-
plete deletion of TREM2 in hTau mice exacerbated tau patholo-
gy–related markers. These studies in primary tauopathy mouse 
models suggest that TREM2 may play a dual role depending on the 
disease stages; during early stages of tau pathology development 
in the absence of neurodegeneration (e.g., hTau mice), decreased 
TREM2 function might promote tau pathology, whereas the com-
plete loss of TREM2 function in advanced stages (PS19 mice) of 
the disease seems to protect from neurodegeneration. However, 
no study to our knowledge has evaluated the impact of AD-associ-
ated TREM2 variants, such as TREM2R47H, in the setting of a model 
of pure tauopathy, nor in a model that develops robust neurode-
generation as is seen in tau-related neurodegenerative diseases.
Given the emerging role for microglia in tau-mediated neuro-
pathology, it is important to understand the role of AD-associat-
ed TREM2 variants that decrease, but do not eliminate, TREM2 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 9 5 6 jci.org   Volume 130   Number 9   September 2020
Figure 1. R47H variant of TREM2 attenuates tau pathology in 9-month-old PS19 mice. Representative images of p-tau staining (AT8, AT180, and PG5) in 
the piriform cortex (A, E, and I) and hippocampus (B, F, and J) from 9-month-old PS19-T2CV and PS19-T2R47H mice. Scale bars: 1 mm. Quantification of the 
percentage area covered by p-tau staining (antibodies AT8, AT180, and PG5) in the piriform cortex (C, G, and K) and hippocampus (D, H, and L). Data are 
presented as the mean ± SEM. Significance was determined using an unpaired, 2-tailed Mann-Whitney test due to the nonparametric data set, except for 
PG5 staining in the hippocampus where an unpaired, 2-tailed t test with Welch’s correction was used due to significantly different variances. *P < 0.05 
(PS19-T2CV, n = 18 and PS19-T2R47H, n = 15/16). (M–O) ELISA results showing concentrations of p-tau (p.Ser202/p.Thr205 and p.Thr181) and total tau and 
p-tau/total tau ratio in the hippocampus were quantified using a human tau–specific (hTau-specific) sandwich ELISA to measure p-tau (M), total tau (N), 
and the p-tau/total tau ratio (O). The levels of p-tau and total tau (M and N) were normalized to total protein concentration. Data are presented as mean ± 
SEM. Significance was determined by an unpaired, 2-tailed Student’s t test except for total tau where an unpaired, 2-tailed Mann-Whitney test was used 
due to the nonparametric data set. *P < 0.05 (PS19-T2CV, n = 17 and PS19-T2R47H, n = 15).
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 9 5 7jci.org   Volume 130   Number 9   September 2020
Effects of TREM2R47H on microglial and astrocytic phenotypes. 
Microglia are critical mediators of tau-dependent neurodegener-
ation (28, 30). Given that the TREM2R47H variant affects microg-
lial function, and that PS19-T2R47H mice exhibited reduced neu-
rodegeneration, we hypothesized that we would also observe 
a state of reduced microglial reactivity as reflected by staining 
with certain microglial markers. We assessed brain sections 
with the myeloid immune cell marker ionized calcium–binding 
adaptor molecule 1 (Iba1) to assess the overall microglial popu-
lation. At 3 months of age, before the onset of overt tau patholo-
gy, there was no change in the surface area covered by microglia 
in the piriform cortex (Supplemental Figure 3, A and C) or the 
hippocampus (Supplemental Figure 3, B and D) between PS19-
T2R47H and PS19-T2CV mice. When we assessed microglial cov-
erage in 9-month-old mice, we observed a marked decrease in 
Iba1 staining in the piriform cortex (Figure 3, B and D) and the 
hippocampus (Figure 3, C and E) of PS19-T2R47H in comparison 
with PS19-T2CV mice. Consistent with these results, Iba1 gene 
expression was reduced by approximately 32% in the cortex of 
PS19-T2R47H versus PS19-T2CV mice (Figure 3A). Importantly, 
reduced microgliosis induced by TREM2R47H in PS19 mice was 
qualitatively similar to previous observations when TREM2 was 
deleted in the same mouse model (25).
We next assessed microglial phenotypic and functional chang-
es in the mice (Figure 4). CD68 (cluster of differentiation 68) label-
ing, a marker of phagolysosomal activity, was drastically reduced in 
the piriform cortex (Figure 4C) and the hippocampus (Figure 4D) of 
9-month-old PS19-T2R47H compared with PS19-T2CV mice. Striking-
ly, there was a decrease in CD68 staining of approximately 78% per 
Iba1+ cell volume detected in PS19-T2R47H versus PS19-T2CV brains 
(Figure 4, E and F), confirming a reduced activation state of PS19-
T2R47H microglia. We also assessed the microglial gene expression 
profile in the cortex of 9-month-old PS19-T2R47H and PS19-T2CV mice 
(Figure 4G). Consistent with lower CD68 staining in PS19-T2R47H 
mice, all the DAM genes tested were downregulated in PS19-T2R47H 
compared with PS19-T2CV mice such as Axl, Cst7, and Cd9. Interest-
ingly, an increase in the expression of the homeostatic gene P2ry12 
was observed in PS19-T2R47H mice, suggesting a more homeostatic 
status of microglia compared with PS19-T2CV mice. On the other 
hand, Cx3cr1 gene expression was decreased in PS19 mice express-
ing TREM2R47H, which may be due to a lower number of microglia 
in these mice. Evaluation of several inflammatory cytokine genes 
revealed a significant decrease in proinflammatory mediators such 
as IL-1α, IL-1β, TNF-α, and TGF-β. IL-6 gene expression was not 
altered by the AD-associated TREM2 variant in PS19 mice, as previ-
ously reported in PS19 knockout for TREM2 (25).
Another brain cell type, astrocytes, also plays an essential 
role in neuroinflammation. It has been previously shown that 
reactive microglia can induce astrogliosis through the produc-
tion of cytokines as IL-1α and TNF-α that can promote neuro-
nal death (32, 33). As previously observed in PS19 mice lacking 
TREM2 (25), we found that glial fibrillary acidic protein (GFAP) 
gene expression, a marker of reactive astrocytes, was decreased 
in 9-month-old PS19-T2R47H compared with PS19-T2CV mice 
(Supplemental Figure 4A). In addition, the GFAP signal was 
drastically reduced in the piriform cortex (Supplemental Figure 
4, B and D) of PS19-T2R47H compared with PS19-T2CV mice, but 
p-tau and total tau using a p-tau–specific (p.Ser202/p.Thr205 
and p.Thr181) and hTau-specific ELISA. We observed no signifi-
cant differences in p-tau (Supplemental Figure 1M) and tau levels 
(Supplemental Figure 1N) or in the p-tau/tau ratio (Supplemental 
Figure 1O) between PS19-T2R47H mice and PS19-T2CV mice. At 9 
months of age, when substantial tau pathology had developed, we 
again observed a significant decrease in hippocampal p-tau stain-
ing on serine 202/threonine 205 (Figure 1, B and D) as well as on 
serine 409 (Figure 1, J and L) between PS19-T2R47H and PS19-T2CV 
mice. There was no significant difference observed on these p-tau 
epitopes in the piriform cortex (Figure 1, A, C, I, and K). Interest-
ingly, staining p-tau on threonine 231 revealed less p-tau in the 
piriform cortex of PS19-T2R47H mice compared with PS19-T2CV 
mice (Figure 1, F and H), but no difference in the hippocampus 
(Figure 1, E and G). Biochemical analysis of p-tau in hippocampal 
brain tissue samples by ELISA revealed no significant differences 
in p-tau level (Figure 1M) but increased total tau levels in PS19-
T2R47H mice compared with PS19-T2CV mice (Figure 1N), resulting 
in a slight but not statistically significant (P = 0.0815) decrease in 
the p-tau/tau ratio (Figure 1O) in PS19-T2R47H mice compared with 
PS19-T2CV mice. These findings demonstrate that the R47H vari-
ant of TREM2 significantly attenuates increases in p-tau on some 
tau sites mostly in the later stages of tau pathology in PS19 mice. 
Interestingly, we (25) and others (27) did not observe lower p-tau 
pathology in PS19 mice with TREM2 deleted compared with PS19 
mice. New studies will be needed to better understand this differ-
ence, but we can hypothesize that the human TREM2CV assessed 
in the present study has a slightly different impact on tau patholo-
gy than mouse TREM2 used in the previous studies.
Effects of TREM2R47H on brain atrophy. Because pathological 
tau is directly linked to neurodegeneration, we next evaluated the 
brain volume of these mice. As expected, no change in brain vol-
ume was detected between PS19-T2R47H and PS19-T2CV mice at 3 
months of age, which is before when neurodegeneration has been 
observed in this model (Supplemental Figure 2, A–E). At 9 months 
of age when tau pathology is much more substantial and neurode-
generation is usually marked in specific brain regions in this mod-
el, the presence of TREM2R47H strongly attenuated brain atrophy 
in PS19 mice compared with mice expressing TREM2CV (Figure 2, 
A and E), similar to PS19 mice lacking TREM2 (25). More specif-
ically, atrophy was significantly decreased by approximately 24% 
in the hippocampus (Figure 2B) and by approximately 34% in the 
piriform and entorhinal cortices (Figure 2D). When atrophy occurs 
in hippocampal and cortical regions, there is concomitant enlarge-
ment of the lateral ventricles. TREM2R47H was also associated with 
extensively reduced ventricular dilatation (~67%) in 9-month-old 
PS19 mice (Figure 2C). Then, we estimated the neuronal loss 
by measuring the thickness of the granule cell layer in the den-
tate gyrus and the pyramidal cell layer in the piriform cortex in 
9-month-old mice. In accordance with changes observed in brain 
volume, both the granule cell layer in the dentate gyrus (Figure 
2, G and I) and pyramidal cell layer in the piriform cortex (Figure 
2, F and H) were visibly and significantly thicker in PS19-T2R47H 
compared with PS19-T2CV mice. This strikingly reduced neurode-
generation suggests an important role for TREM2 in regulating 
tau-mediated brain atrophy, with the R47H variant of TREM2 
being neuroprotective in the setting of tauopathy.
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in synapses of PS19 mice and AD patients (34). Synaptic C1q 
accumulation correlated with augmented microglial engulf-
ment of synapses in vivo and decline of synapse density in 
vitro. Because we previously showed that C1q gene expression 
can be modulated by the absence of TREM2 in PS19 mice, we 
assessed how TREM2R47H affected protein and gene expression 
not in the hippocampus (Supplemental Figure 4, E and C). Tak-
en together, these data suggest that the R47H variant of TREM2 
strongly reduced microglial activation and the concomitant 
astrogliosis in the setting of tauopathy.
Effects of TREM2R47H on synapses. A recent study by Dejanovic 
et al. reported a striking accumulation of complement C1q 
Figure 2. R47H variant of TREM2 decreases neurodegeneration in 9-month-old PS19 mice. (A) Representative images of PS19-T2CV and PS19-T2R47H brain 
sections stained with Sudan black at 9 months of age. Scale bars: 1 mm. (B–E) Quantification of the average volume of the hippocampus (B), ventricles 
(C), entorhinal and piriform cortices (D), and half brain minus ventricle (E). (F–I) Thickness of the pyramidal layer of the piriform cortex (F and H) and the 
granule cell layer of the dentate gyrus (DG) (G and I) in 9-month-old mice with cresyl violet staining. Data are presented as mean ± SEM. Significance was 
determined by an unpaired, 2-tailed Student’s t test. *P < 0.05, **P < 0.01 (9-month-old: PS19-T2CV, n = 18/19 and PS19-T2R47H, n = 16).
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levels of C1q, as well as C1q+ synapses in PS19 mice. First, we 
found that C1qa gene expression was reduced by approximately 
60% in the cortex of 9-month-old PS19-T2R47H compared with 
the PS19-T2CV mice (Figure 5C). Consistent with these findings, 
C1q staining and confocal analysis revealed reduced C1q stain-
ing in PS19-T2R47H mice (Figure 5B). To evaluate C1q accumula-
tion at putative synapses, we then assessed the number of punc-
ta labeled with pre- and postsynaptic markers that were positive 
for C1q. PSD-95+ puncta and synapsin+ puncta positive for C1q 
were significantly decreased in PS19-T2R47H versus PS19-T2CV 
mice (Figure 5, A, D, and E).
We next assessed whether the decrease in C1q-opsonized 
synaptic-marker puncta and attenuated brain atrophy would 
correspond to improved synaptic integrity in PS19-T2R47H mice. 
We therefore quantified presynaptic (synapsin) and postsynap-
tic (PSD-95) marker puncta in PS19-T2R47H and PS19-T2CV mice 
in the polymorphic layer of the piriform cortex (Figure 6A). 
This revealed significantly more pre- and postsynaptic puncta 
in PS19-T2R47H compared with PS19-T2CV mice (Figure 6, B and 
C). As many such puncta are nonsynaptic (35, 36), we turned to 
a more specific method of quantifying intact synaptic loci. Using 
SEQUIN analysis (synaptic evaluation and quantification by 
imaging of nanostructure) (36), a super-resolution imaging and 
image analysis platform for quantifying synaptic loci, we detect-
ed significantly more intact synaptic loci in PS19-T2R47H versus 
PS19-T2CV mice (Figure 6D). To better understand ultrastructur-
al changes at synapses under these conditions, electron micros-
copy was undertaken in a small parallel cohort in the polymor-
phic layer of the piriform cortex. Synapses from PS19-T2CV mice 
exhibited several dystrophic features, including swollen presyn-
aptic elements, accumulation of enlarged autophagosomes, and 
a reduced number of synaptic vesicles (Figure 6E). Moreover, 
mitochondria often appeared swollen, a feature also seen with 
hypoxia, and abundant dark dendritic spines, indicative of post-
synaptic cellular stress, were visible (Figure 6E). In contrast, 
electron microscopic images from PS19-T2R47H mice revealed 
improved synaptic integrity with fewer autophagosomes, pre-
served mitochondrial ultrastructure, and less frequent dark den-
drites/spines and axon terminals (Figure 6F). Importantly, these 
results demonstrate that reduced brain atrophy in PS19-T2R47H 
mice is associated with decreased synapses with dystrophic fea-
tures and better preservation of pre- and postsynaptic elements.
Effects of TREM2R47H on microglial phagocytosis of synaptic ele-
ments. Regarding the role of TREM2 in microglial phagocytosis 
(37, 38) and the fact that we observed strong reduction of CD68+ 
phagolysosomes in microglia of PS19-T2R47H versus PS19-T2CV 
mice, we then hypothesized that impairment of microglial phago-
cytosis in 9-month-old PS19-T2R47H mice is responsible for the 
decreased synapse loss. A previous study by Filipello et al. (39) 
demonstrating that microglial TREM2 is required for synapse 
elimination during the early stages of brain development strong-
ly support this hypothesis. Costaining and confocal analysis for 
the microglial phagolysosomal marker CD68 and the postsyn-
aptic marker PSD-95 revealed significantly fewer PSD-95 punc-
ta in CD68+ vesicles per microglia in the polymorphic layer of 
the piriform cortex of 9-month-old PS19-T2R47H compared with 
PS19-T2CV mice (Figure 7, A and B). Consistent with the higher con-
tent of synapses in 9-month-old PS19-T2R47H mice, these data show 
an important role for TREM2 in synapse loss in PS19 mice that is 
decreased by TREM2R47H in a pure tauopathy model.
Given these results, to assess the relevance of these findings in 
the setting of tauopathy in human AD, we assessed whether the brains 
of individuals who were TREM2-variant carriers who had AD exhib-
ited similar reductions of postsynaptic puncta engulfed in CD68+ 
phagolysosomes compared with AD cases expressing TREM2CV. We 
stained prefrontal cortex tissue from late-onset AD TREM2R47H and 
TREM2R62H individuals and their case-matched controls for Iba1, 
CD68, and PSD-95. R62H is another TREM2 variant associated with 
an increased risk for AD (40, 41). Consistent with our mouse data, we 
detected significantly fewer PSD-95 puncta engulfed in CD68+ vesi-
cles per microglia in AD TREM2R47H and TREM2R62H brains compared 
with AD brains with TREM2CV (Figure 7, C and D). The detection of 
reduced synaptic phagocytosis by microglia expressing R47H or 
R62H variants of TREM2 in AD cases confirms the defective synapse 
elimination by microglia with TREM2 loss of function. Taken togeth-
er, these data suggest that microglia expressing TREM2R47H phago-
cytose fewer synapses due to lower C1q accumulation in synapses, 
resulting in neuroprotection in the setting of tauopathy.
Discussion
TREM2R47H has been associated with higher risk of developing 
AD. Data from animal models and humans suggest that the 
Figure 3. R47H variant of TREM2 decreases microgliosis in 9-month-
old PS19 mice. (A) Expression of microglial marker Iba1 in the cortex of 
9-month-old PS19-T2CV and PS19-T2R47H mice (PS19-T2CV, n = 11 and PS19-
T2R47H, n = 10). (B and C) Quantification of the percentage area covered by 
Iba1 staining in the piriform cortex (B) and hippocampus (C) (PS19-T2CV, 
n = 19 and PS19-T2R47H, n = 18). (D and E) Representative images of Iba1 
staining in the piriform cortex (D) and hippocampus (E) from PS19-T2CV and 
PS19-T2R47H mice. Scale bars: 0.5 mm. Data are presented as mean ± SEM. 
Significance was determined using an unpaired, 2-tailed Mann-Whitney 
test due to the nonparametric data set. *P < 0.05, **P < 0.01.
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Figure 4. Reduced microglial activation and inflammatory gene expression in 9-month-old PS19-T2R47H versus PS19-T2CV mice. (A and B) Representative 
images of CD68 staining from 9-month-old PS19-T2CV (A) and PS19-T2R47H (B) brains. (C and D) Quantification of the percentage area covered by CD68 stain-
ing in the piriform cortex (C) and hippocampus (D) (PS19-T2CV, n = 18 and PS19-T2R47H, n = 18). (E) Confocal images and 3D reconstruction of CD68+ structures 
within Iba1+ microglia in PS19-T2CV and PS19-T2R47H. Scale bars: 10 μm. (F) Quantification of CD68+ structures per Iba1 volume (PS19-T2CV, n = 19 and  
PS19-T2R47H, n = 15). Data are presented as mean ± SEM. Significance was determined using an unpaired, 2-tailed Mann-Whitney test due to the nonpara-
metric data set. **P < 0.01, ***P < 0.001, ****P < 0.0001. (G) Heatmap analysis of microglial gene expression in 9-month-old PS19-T2CV and PS19-T2R47H 
piriform cortex generated by hierarchical gene clustering based on genotypes. DAM genes, disease-associated microglia genes. For IL-1α, P2ry12, and TNF-α, 
significance was determined by an unpaired, 2-tailed Student’s t test. For Apoe, Cst7, IL-1β, and IL-6, significance was determined using an unpaired, 2-tailed 
Mann-Whitney test due to the nonparametric data set. For all other analyses, significance was determined by an unpaired, 2-tailed t test with Welch’s 
correction due to significantly different variances. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (PS19-T2CV, n = 11 and PS19-T2R47H, n = 10).
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due to lower C1q accumulation in synapses, resulting in neuro-
protection in the setting of tauopathy.
Although the TREM2R47H variant has been associated with a 
higher risk of developing AD, we observed delayed progression 
of p-tau pathology and neurodegeneration in the hippocampus of 
PS19-T2R47H mice. Surprisingly, in 2 previous studies of PS19 mice 
with complete absence of TREM2, no change in tau pathology has 
been reported (25, 26). We do not know the answer to why TREM2R47H 
decreases some p-tau species at 9 months of age compared with 
TREM2CV in PS19 mice, whereas TREM2 deletion did not have this 
effect compared with mice expressing murine TREM2 (25). Howev-
er, we can speculate that this dissimilarity results from the slightly 
different age of the mice used between the 2 studies or because of the 
difference between mouse and human TREM2. Indeed, in the Leyns 
et al. study (25), the PS19 mice expressed mouse TREM2, which 
may have a slightly different overall effect compared with human 
TREM2CV used in this study. Unlike studies on PS19 mice, complete 
deletion of TREM2 in hTau mice exacerbated tau phosphorylation 
and insolubility (27). Despite the apparent confusion regarding the 
impact of TREM2 on tau pathology, we hypothesized that reduced 
tau pathology in PS19-T2R47H mice results from decreased microgli-
al activation. Indeed, in a mouse model of tau propagation using an 
injection of the AAV2/6-SYN1 promoter driving the expression of a 
human P301L tau mutant into the brain, Asai et al. report that deplet-
ing microglia dramatically suppressed tau propagation (44). More-
over, microglial activation has been shown to correlate with a defi-
cit in spatial memory and the spread of tau pathology in hTau mice 
(45). Recently, our lab and others demonstrated that the progres-
sion of p-tau pathology is also driven by microglia in PS19 mice (28, 
30). Moreover, the same study by Shi et al. (28) demonstrated that 
microglia-mediated damage was the leading force driving neurode-
generation in a pure-tauopathy mouse model. Similarly, Leyns et al. 
likely reason for this effect is that decreased TREM2 function 
leads to a decreased microglial response to Aβ deposition, 
increased Aβ-associated local neurotoxicity, and an exacer-
bation of Aβ-induced tau seeding and spreading (15, 42, 43). 
However, during the time course of AD, Aβ aggregation and 
accumulation in the neocortex occurs over a 15- to 25-year 
period before symptom onset. Tau aggregation and pathology 
development in the neocortex does not occur until just a few 
years before the onset of cognitive decline. Thus, while TREM2 
signaling may protect against Aβ-related changes in the brain, 
the role of TREM2 signaling during the neocortical tau phase 
(symptomatic phase) of AD and in primary tauopathies may 
not be the same. This is critical to understand, as therapeutic 
targeting of TREM2 may differ depending on the stage of the 
disease. Our study unveils a role of TREM2 in the control of 
tau-mediated synaptic elimination and neurodegeneration in 
the setting of pure tauopathy that may also be relevant to the 
neocortical tau phase of AD. Surprisingly, we demonstrated 
that the AD-associated TREM2R47H variant strongly reduces the 
development of brain atrophy, as well as synapse loss in PS19 
mice. Importantly, in the presence of TREM2R47H, tau phos-
phorylation was decreased, suggesting that p-tau pathogene-
sis might be influenced by TREM2 function. Further analysis 
revealed decreased microglial activation and reduced expres-
sion of several DAM genes in PS19-T2R47H mice. These results 
indicate that TREM2 contributes to the microglial response 
to tau pathology or tau-mediated impairment. Importantly, a 
decrease in phagocytosis of postsynaptic elements by microg-
lia expressing TREM2R47H was detected in PS19 mice and AD 
patients and can, at least in part, explain the decrease in synap-
tic damage observed in PS19-T2R47H mice. Finally, we observed 
that microglia expressing TREM2R47H phagocytose fewer synapses 
Figure 5. R47H variant of TREM2 lowers C1q+ synaptic markers in 9-month-old PS19 mice. (A) Representative images from confocal analysis of presynaptic 
(synapsin in green) and postsynaptic (PSD-95 in red) markers, and C1q (purple) of 9-month-old PS19-T2CV and PS19-T2R47H piriform cortex. Scale bars: 3 μm. 
Quantification of the percentage of C1q volume (B), C1q+ PSD-95 puncta number (D), and C1q+ synapsin puncta number (E) (PS19-T2CV, n = 20 and PS19-T2R47H, 
n = 17). (C) Expression of cortical C1qa mRNA in 9-month-old PS19-T2CV and PS19-T2R47H mice (PS19-T2CV, n = 11 and PS19-T2R47H, n = 10). Data are presented as 
mean ± SEM. Significance was determined using an unpaired, 2-tailed Mann-Whitney test due to the nonparametric data set. **P < 0.01, ***P < 0.001.
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Figure 6. R47H variant of TREM2 reduces synapse loss in 9-month-old PS19 mice. (A) Representative images from confocal analysis of presynaptic 
(synapsin in green) and postsynaptic (PSD-95 in red) markers of 9-month-old PS19-T2CV and PS19-T2R47H piriform cortex. Scale bars: 3 μm. (B–D) Quantifica-
tion of puncta numbers from PSD-95 (B) and synapsin (C) staining, and SEQUIN quantification of synaptic loci (D). Data are presented as mean ± SEM. A 
Mann-Whitney test was used to determine statistical significance for PSD-95 puncta due to the nonparametric data set. For all other graphs, significance 
was determined by an unpaired, 2-tailed t test with Welch’s correction due to significantly different variances. **P < 0.01 (PS19-T2CV, n = 20 and PS19-T2R47H, 
n = 17). (E and F) Electron microscopic images of the polymorphic layer of the piriform cortex from (E) a PS19-T2CV mouse and (F) a PS19-T2R47H mouse. Images 
were obtained at ×9300 and ×6800  magnification, respectively, using an FEI Tecnai Spirit G2 transmission electron microscope. Purple = healthy terminal 
axons, light blue = healthy dendritic spines, light pink = healthy mitochondria, yellow = dystrophic terminal axons, orange = altered mitochondria, red arrow = 
dark dendritic spines, green arrow = dark dendrite. Asterisks indicate autophagosomes.
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attenuation in PS19 mice observed in this study. Because synapse 
loss is well characterized in mouse models of tauopathies (29, 
46–48), and TREM2 has been shown to play a key role in synap-
tic pruning during brain development (39), we then hypothesized 
that TREM2 loss of function leads to lower brain atrophy in PS19 
mice by inhibiting synaptic phagocytosis by microglia. Indeed, our 
lab previously reported higher levels of PSD-95, a postsynaptic 
marker, in PS19-TREM2-KO compared with PS19 mice (25). We 
confirmed that PS19-T2R47H mice have strikingly more pre- and 
postsynaptic markers, as well as better-maintained pre- and post-
synaptic interactions compared with PS19-T2CV mice.
Although the TREM2R47H protective effect against tau-medi-
ated brain atrophy and synapse loss seems clear in this study, the 
possible mechanisms underlying this phenomenon are multiple. 
First, chronic immune activation is known to result in high levels 
and Sayed et al. previously reported that complete loss of TREM2 
protects against tau-mediated brain atrophy as well as lower micro-
gliosis (25, 26). Importantly, even though we observed decreased 
tau pathology in PS19-T2R47H mice, the neuroprotective effect 
by TREM2R47H characterized in this study is likely attributable to 
reduced microglia-dependent neuronal damage rather than a direct 
effect on p-tau pathology per se. Indeed, decreased tau pathology 
in the piriform cortex has been observed only with p.Thr231, while 
preserved brain volume, pyramidal layer thickness, and synaptic 
integrity is reported in the piriform cortex of PS19-T2R47H mice as 
well as a strong reduction of microgliosis. Moreover, Leyns et al. 
previously reported a neuroprotection induced by TREM2 dele-
tion in PS19 mice without a change in tau pathology but with low-
er microgliosis (25). Thus, diminished microgliosis resulting from 
the R47H variant of TREM2 seems to explain the brain atrophy 
Figure 7. R47H variant of TREM2 alters synapse engulfment by microglia in 9-month-old PS19 mice and human TREM2 variant carriers (R47H and 
R62H). (A) Representative confocal images and relative 3D surface rendering showing volume reconstruction of CD68 (green) and engulfed PSD-95 
puncta (red), detected within microglial CD68+ structures of 9-month-old PS19-T2CV and PS19-T2R47H piriform cortex. Scale bars: 5 μm. (B) Quantification 
of engulfed PSD-95 puncta within CD68+ vesicles per microglia. Data are presented as mean ± SEM. Significance was determined using an unpaired, 
2-tailed Mann-Whitney test due to the nonparametric data set. ***P < 0.001 (PS19-T2CV, n = 19 and PS19-T2R47H, n = 15). (C) Representative image from 
confocal analysis of microglia (white), CD68 (green), and engulfed PSD-95 puncta (red), detected within microglial CD68+ structures in TREM2R47H (red 
triangle) and TREM2R62H (yellow square) AD patients (AD-T2R47H/R62H) and case-matched TREM2CV AD controls. Scale bars: 5 μm. (D) Quantification of 
engulfed PSD-95 puncta within CD68+ structures (arrowheads) per microglia. Data are presented as mean ± SEM. Significance determined by paired, 
2-sided t test. *P < 0.05 (AD-T2CV, n = 9; AD-T2R47H, n = 5; and AD-T2R62H, n = 5).
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 9 6 4 jci.org   Volume 130   Number 9   September 2020
Therefore, we hypothesize that AD-associated TREM2 variants 
increase AD risk by promoting Aβ-mediated local toxicity and 
facilitate tau seeding and spreading in the early pathological stag-
es of the disease. However, in the later stages of the disease (i.e., 
symptomatic stage) and in primary tauopathies, when substantial 
tau pathology has developed, AD-associated TREM2 variants 
might slow down tau-mediated synapse loss in the brain through 
reduction of synapse phagocytosis by microglia. It is important to 
note that complete loss of function of TREM2 in humans results 
in Nasu-Hakola disease characterized by cerebral degeneration 
and white matter damage (60, 61). However, partial loss of func-
tion of TREM2 as seen with the TREM2R47H mutation in the het-
erozygous or homozygous condition is associated with increased 
risk for AD (not with Nasu-Hakola disease) (9, 10, 62). Thus, it 
may be that decreasing but not ablating TREM2 function during 
the tau phase of neurodegeneration results in neuroprotection 
not only in mouse models but also in humans.
Taken together, our data show that TREM2 plays a key role in 
neurodegeneration in the context of tau pathology. Surprisingly, 
the AD-associated TREM2R47H variant was strongly neuroprotec-
tive, probably because of decreased chronic inflammation and 
decreased synaptic phagocytosis. While research on microglia 
and TREM2 in AD has largely focused on TREM2 interactions 
with Aβ pathology, this study suggests that TREM2 can directly 
affect tau pathology and tau-mediated neurodegeneration in the 
brain. This study raises new important questions about targeting 
TREM2 as a therapeutic approach to treat AD. Indeed, stimulat-
ing the TREM2 pathway using antibodies or drugs is thought to 
be a promising therapeutic strategy to treat or slow down AD pro-
gression. However, this study suggests that TREM2 exacerbates 
tau-mediated neurodegeneration in the later stages of the dis-
ease when tau pathology is prominent. This study highlights the 
complexity of using TREM2 as a target to treat AD or a primary 
tauopathy. Moving forward, it will be important to identify and 
establish the appropriate therapeutic window using close moni-
toring of neurodegenerative stage and inflammation-related AD 
biomarkers to either stimulate or inhibit the TREM2 pathway 
based on the disease and its stage. This should be possible with 
the use of fluid- and imaging-based biomarkers. Importantly, this 
study revealed for the first time to our knowledge that the AD- 
associated TREM2R47H variant is protective against tau pathology 
and tau-mediated neurodegeneration.
Methods
Animals. PS19 transgenic mice expressing human P301S 1N4R 
mutated tau driven by the PrP promoter were purchased from The 
Jackson Laboratory (stock 008169). PS19 mice were backcrossed 
and maintained on a mouse TREM2-KO background (T2KO). PS19-
T2KO were crossed with mice that had been engineered using BAC 
technology to express either human TREM2CV or the AD-associated 
TREM2R47H on a mouse T2KO background (15). These BAC trans-
genic mice carrying human TREM2 (common variant or R47H vari-
ant), TREML1, and TREML2 were backcrossed with T2KO mice 
to yield mice that express either TREM2CV or TREM2R47H in the 
absence of mouse TREM2. The use of BAC TREM2 models prohib-
ited the ability to compare littermates with different genotypes in 
this study. Because of the fact that male PS19 mice at different ages 
of several proinflammatory cytokines such as TNF-α or IL-1β that 
can induce synaptic excitotoxicity (49–52), and we show that PS19-
T2R47H mice have a robust reduction in the expression of TNF-α 
and IL-1β, as well as several other proinflammatory cytokines com-
pared with PS19-T2CV. Second, as previously mentioned, TREM2 
is well known for its functions in promoting microglial cell sur-
vival (53) and in cellular phagocytosis (37, 54, 55). Filipello et al. 
also determined that TREM2 is essential for microglia-mediated 
synaptic refinement during the early stages of brain development 
and that TREM2 deletion resulted in impaired synapse elimination 
(39). Moreover, a recent study by Sheng at al. reported that TREM2 
deficiency ameliorates synaptic deficits in 8-month-old APP/PS1 
mice, an amyloid mouse model (56). In PS19-T2R47H mice, we con-
firmed the reduction of microglial phagocytic properties with fewer 
CD68+ phagolysosomes within microglia. In addition, a decrease 
in number of postsynaptic puncta engulfed in CD68+ vesicles was 
observed not only in PS19-T2R47H mice, but also in AD patients har-
boring either the R47H mutation or the R62H mutation, another 
AD-associated TREM2 variant (41, 57, 58). These data suggest that 
partial loss of function induced by AD-associated TREM2 variants 
might protect against aberrant synaptic phagocytosis by microglia 
due to chronic inflammation. The impaired phagocytosis of syn-
apses by microglia might also be due to lower C1q accumulation 
in synapses. C1q, the initiating protein of the classical complement 
cascade, is increased and associated with synapses before overt 
amyloid plaque deposition in AD and inhibition of C1q reduces the 
number of phagocytic microglia, as well as the extent of early syn-
aptic loss in familial AD-mutant hAPP (J20) transgenic mice (59). 
More recently, Dejanovic et al. (34) reported a striking accumula-
tion of complement C1q in synapses of PS19 mice and AD patients. 
Moreover, they demonstrated an association of synaptic C1q accu-
mulation with augmented microglial engulfment of synapses and a 
decrease in synapse density in vitro. Interestingly, we reported that 
despite more synapses in PS19-T2R47H mice, there was dramatically 
less C1q-opsonized synapsin and fewer PSD-95 puncta detected in 
the brain of these mice in comparison with PS19-T2CV mice. This is 
consistent with lower C1q accumulation in synapses of PS19-T2R47H 
mice compromising the signal for microglia to engulfed them, pre-
serving synaptic density. Importantly, a combination of all these 
mechanisms resulting from the inhibition of a chronic inflammato-
ry vicious circle remains conceivable here.
Obviously, an evident question emerges from this study: how 
does TREM2R47H increase the risk of developing AD, but appear 
protective against tau-mediated synapse loss? The answer might 
be amyloid, tau, and time dependent. Recently, we have found 
that TREM2 deficiency increases amyloid-induced tau spread-
ing (42), which is a phase of AD pathogenesis that precedes the 
tau-linked neurodegeneration phase of AD. In this study (42), we 
showed that TREM2-KO or the AD-associated TREM2R47H variant 
reduces microgliosis around Aβ plaques. Importantly, TREM2-
KO and the AD-associated TREM2R47H variant strongly promot-
ed tau seeding and spreading in the form of neuritic plaque tau 
aggregates. In addition, decreased plaque-associated microglio-
sis in these mice corresponded with higher periplaque Aβ42 accu-
mulation and formation of neuritic dystrophy around plaques. 
These findings demonstrate a critical role for TREM2 in microg-
lia in inhibiting a key element of Aβ-facilitated tau pathology. 
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human-specific biotinylated HT7 for detection for tau ELISA and 
using HJ14.5 (in-house p.Thr181-tau antibody) as the coating anti-
body and human-specific biotinylated AT8 for detection for p-tau 
ELISA. Briefly, 96-well half-area plates were coated with 20 μg/mL 
of either HJ14.5 or Tau-5 antibody and incubated at 4°C overnight. 
The next day, the plate was blocked in 3% BSA (RPI Corp.) in PBS 
for 1 hour at 37°C. Next, peptide standards and samples were dilut-
ed in sample buffer (0.25% BSA/PBS, 1× protease inhibitor, 300 
mM Tris pH 7.4, PBS), loaded onto the plate, and incubated at 4°C 
overnight. On the third day, 0.3 μg/mL of biotinylated AT8 for p-tau 
ELISA (Thermo Fisher Scientific, MN1020B) or biotinylated HT7 
for tau ELISA (Thermo Fisher Scientific, MN1000B) was applied to 
the plate for 1.5 hours at 37°C, and then Streptavidin-poly-HRP-40 
(1:10,000 for tau and 1:6,000 for p-tau) (Fitzgerald) was applied for 
1.5 hours at room temperature. TMB Superslow Substrate solution 
(MilliporeSigma) was added and the plates were read at 650 nm on 
a BioTek plate reader after developing for 30 minutes at room tem-
perature. All samples were run in duplicate.
Immunohistochemistry. For staining microglia (Iba1, rabbit poly-
clonal, 1:5,000; Wako, 019-19741) and p-tau (AT8, mouse monoclo-
nal, 1:500; Thermo Fisher Scientific, MN1020B — AT180, mouse 
monoclonal, 1:500; Thermo Fisher Scientific, MN1040 — PG5, 
mouse monoclonal, 1:500 [gift from Peter Davies, Feinstein Insti-
tutes for Medical Research, Northwell Health, Manhasset, New 
York, USA]), sections were washed 3 times in TBS for 5 minutes and 
blocked in 0.3% hydrogen peroxide for 10 minutes. After washing, 
sections were blocked in 3% milk in TBS with 0.25% Triton X-100 
(TBSX) for 30 minutes. Primary antibody was diluted in 3% milk/
TBSX, and the sections were incubated in the primary antibody over-
night at 4°C. The next day, sections were washed and incubated with 
secondary antibody diluted in 3% milk/TBSX for 1 hour. For AT8 
staining, after washing, sections were incubated in ABC Elite solu-
tion (VectaStain, PK-6100) for 1 hour, prepared following the man-
ufacturer’s instructions, followed by another washing step. For Iba1, 
AT180, and PG5 staining, after washing, sections were incubated 
with HRP-conjugated secondary antibodies for 1 hour at room tem-
perature (1:500; Jackson Laboratory, 111-035-003). Sections were 
developed in DAB solution (Vector Laboratories, SK4103), washed, 
and mounted on slides. After drying overnight, the slides were dehy-
drated in increasing ethanol concentrations followed by xylene and 
coverslipped with Cytoseal 60 (Thermo Fisher Scientific, 8310). 
Slides were scanned on the NanoZoomer 2.0-HT system. Images 
were further processed and quantified with the use of Fiji software 
version 1.51. All areas were quantified in 2 to 3 sections (300 μm 
apart from each other) per mouse.
Immunofluorescence. Immunofluorescence staining was per-
formed as previously described (36). Briefly, free-floating tissue was 
placed in 12-well plates with Netwell inserts (Corning) containing 
PBS. Blocking solution and primary and secondary antibody mix-
tures were centrifuged at 17,000 g for 5 minutes just before use. Tis-
sue was rinsed 3 times, 5 minutes each, in PBS followed by blocking 
in 20% normal goat serum (NGS) in PBS for 1 hour at room tempera-
ture. Tissue was then incubated overnight at room temperature with 
primary antibodies (CD68, rat monoclonal, 1:500; AbD SeroTec, 
MCA1957), Iba1 (goat polyclonal, 1:5,000; Abcam, ab5076), PSD-95 
(rabbit polyclonal, 1:200; Thermo Fisher Scientific, 51-6900), syn-
apsin-1/2 (guinea pig polyclonal, 1:500; Synaptic Systems, 106004), 
have greater tau pathology and neurodegeneration, and less vari-
ability than female mice (63, 64), only males were used for analysis 
in this study. All mice were on the C57BL/6 background.
Sample collection. At time of death, mice were anesthetized 
with i.p. pentobarbital (200 mg/kg). Blood samples were collected 
in EDTA-treated tubes before cardiac perfusion with with 3 U/mL 
heparin in cold Dulbecco’s PBS. Blood samples were spun down (10 
minutes, 2000 g, 4°C), and blood plasma was collected. Brains were 
carefully extracted and cut into 2 hemispheres. The left hemisphere 
was collected for immunostaining and fixed in 4% paraformaldehyde 
overnight before being transferred to 30% sucrose and stored at 4°C 
until they were sectioned. Brains were cut coronally into 50-μm sec-
tions on a freezing sliding microtome (Leica, SM1020R) and stored 
in cryoprotectant solution (0.2 M PBS, 15% sucrose, 33% ethylene 
glycol) at –20°C until use. The right hemisphere was dissected to iso-
late the hippocampus and the cortex for biochemical analysis, and 
the tissue was kept at –80°C until analyzed.
For electron microscopy, 3 mice per group were anesthetized 
with i.p. pentobarbital (200 mg/kg) and perfused with 0.1% glutar-
aldehyde in 4% paraformaldehyde (65). Fifty-micrometer-thick cor-
onal sections of the brain were cut in sodium phosphate buffer using 
a vibratome (Vibratome series 1000 sectioning system) and stored 
at –20°C in cryoprotectant until further processing (66).
Volumetric analysis of brains sections. Every sixth brain section 
(300 μm between sections) starting rostrally at bregma –1.23 mm to 
the dorsal end of the hippocampus at bregma –2.73 mm were mount-
ed on slides and allowed to dry overnight for each mouse. The fol-
lowing day, mounted sections were stained with 0.1% Sudan black 
in 70% ethanol at room temperature for 20 minutes, then washed 
in 70% ethanol 3 times for 1 minute. The sections were washed in 
Milli-Q water and coverslipped with Fluoromount (Southern Bio-
tech). Slides were imaged with the NanoZoomer 2.0-HT system 
(Hamamatsu Photonics) and areas of interest measured using the 
NDP viewer software (Hamamatsu Photonics). The volume for each 
region of interest was calculated using the following formula: vol-
ume = (summary of areas) × 0.3 mm.
Neuronal layer thickness measurement. Three sections (bregma –2.0, 
–2.4, and –2.8 mm) per mouse were mounted and allowed to dry over-
night. The following day, sections were stained in cresyl violet for 6 min-
utes at room temperature. The slices were then sequentially dehydrated 
in increasing ethanol concentrations followed by xylene and covers-
lipped with Cytoseal 60 (Thermo Fisher Scientific, 8310-16). The thick-
ness of the pyramidal cell layer of the piriform cortex and dentate gyrus 
granular cell layer was measured by drawing a scale perpendicular to 
the cell layer in all 3 slices and taking the average value for each mouse.
Brain extraction and tau and p-tau ELISA. Half of the hippocam-
pus was weighed and homogenized using a pestle with 20 μL buf-
fer/mg tissue (10 mM Tris-HCl pH 7.4, 0.8 M NaCl, 1 mM EDTA, 2 
μM DTT, cOmplete and PhosStop [both Roche], and 10% sucrose). 
Samples were centrifuged for 10 minutes at 10,000 g and 4°C. 
Supernatant was removed and kept on ice while the pellet was re-ho-
mogenized in the same volume of buffer with a sonicator at 30% 
amplitude, 1 second on/1 second off pulse, for 1 minute, and centri-
fuged for 10 minutes at 10,000 g and 4°C. The 2 supernatants were 
pooled together and frozen until used. The concentration of tau and 
p-tau was quantified by sandwich ELISA as previously described 
(42) using Tau-5 (in-house antibody) as the coating antibody and 
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experiments. Human samples were obtained from the Alzheimer’s 
Disease Research Center at Washington University. TREM2R47H and 
TREM2R62H AD cases were paired with TREM2CV AD cases matching 
age, sex, and APOE genotype (Supplemental Table 1).
Gene expression. We extracted total RNA from mouse cortex 
with the RNeasy Mini Kit (QIAGEN) and prepared cDNA with the 
High-Capacity RNA-to-cDNA kit (Applied Biosystems), follow-
ing manufacturers’ instructions. Gene expression analysis was 
performed using microarray in collaboration with the Genome 
Technology Access Core at Washington University. Using TaqMan 
probes, the relative gene expression was quantitatively measured 
using Fluidigm Biomark HD with integrated fluidic circuits.
Tissue preparation for electron microscopy. Three PS19-T2CV mice 
and 2 PS19-T2R47H mice were used for electron microscopy. In each 
animal, brain sections containing the polymorphic layer of the pir-
iform cortex (bregma –1.67 mm to –1.91mm) were selected based 
on the stereotaxic atlas of Paxinos and Franklin (67). The sections 
were washed 3 times, 10 minutes each, with PBS, pH 7.4, and then 
incubated 1 hour in a solution of equal volume of 3% potassium fer-
rocyanide in phosphate buffer (PB, 0.1 M, pH 7.4) and 4% aqueous 
osmium tetroxide. Following washing 3 times, 5 minutes each in PBS, 
tissues were incubated 20 minutes in a thiocarbohydrazide solution 
and washed again 3 times, 5 minutes each in double-distilled water 
(ddH2O). A 30-minute incubation of 2% osmium tetroxide (from 
4% stock, diluted in ddH2O) was then performed. The brain sec-
tions were washed 3 times, 5 minutes each in ddH2O and dehydrated 
with an increasing amount of ethanol (5-minute washes each): 35% 
(twice), 50%, 70%, 80%, 90%, 100% (thrice). After dehydration in 
ethanol, the sections were washed 3 times, 5 minutes each, in propyl-
ene oxide and were emerged overnight in Durcupan resin. The fol-
lowing day, tissues were placed between 2 ACLAR sheets (Electron 
Microscopy Sciences) covered with a thin layer of resin and incubat-
ed 3 days at 55°C to polymerize.
Ultramicrotomy and transmission electron microscopy. The poly-
morphic layer of the piriform cortex was excised from the ACLAR 
sheet with a razor blade and glued onto a resin block. The tissues 
were then cut using an ultramicrotome (Leica Ultracut UC7), first 
with a thickness of 300 nm to confirm the region of interest using 
toluidine blue, and finally at a thickness of 70 nm. The ultrathin 
sections were collected onto copper-mesh grids. The polymorphic 
layer was imaged at 80 kV using a transmission electron microscope 
(FEI Tecnai Spirit G2) equipped with a Hamamatsu ORCA-HR digi-
tal camera (10 MP). The user was blinded to the experimental con-
ditions during imaging and ultrastructural interpretation. Images 
of the synaptic neuropil were randomly acquired throughout the 
region of interest so as to avoid bias. Sixteen to 20 nonoverlap-
ping images at a magnification between ×6,800 and ×13,500 were 
obtained per animal. Overall, between 575 μm2 and 729 μm2 of the 
synaptic neuropil were imaged per animal.
Images were analyzed using the software ImageJ (NIH). For the 
qualitative analysis of synaptic ultrastructure, the following parameters 
were considered: the presence and size of autophagosomes; the pres-
ence of altered mitochondria; the presence of dark dendrites, dendrit-
ic spines, or axon terminals; and the presence of dystrophic synapses. 
Dark cells (e.g., microglia, neurons) are characterized by ultrastructur-
al signs of oxidative stress (endoplasmic reticulum dilation, conden-
sation of the nucleoplasm and cytoplasm, altered mitochondria) (68, 
and C1q (mouse monoclonal, 1:50; Abcam, ab71940) in 10% NGS 
containing 0.3% Triton X-100 in PBS. The following day, sections 
were rinsed 3 times, 5 minutes each, in PBS followed by incubation 
in secondary antibodies (Thermo Fisher Scientific; 1;500) in 10% 
NGS containing 0.3% Triton X-100 in PBS for 4 hours at room tem-
perature. Sections were mounted, dried at room temperature, briefly 
rinsed in distilled water, and then coverslipped. Mounting medium 
(~150 μL/slide) was prepared the day of use by mixing Tris-MWL 
4-88 (Electron Microscopy Sciences, 17977-150) with AF300 (Elec-
tron Microscopy Sciences, 17977-25) at a 9:1 ratio.
Image acquisition for immunofluorescence. Images were acquired 
on an LSM 880 microscope with AiryScan detector (Zeiss). Quan-
tification was performed using a semiautomated pipeline based on 
MATLAB (MathWorks) and Imaris 9.3.1 software (Bitplane) as pre-
viously described (36). Spots were detected for each channel using 
an x-y size of 0.2 μm, a z size of 0.6 μm, and automated background 
subtraction. A 0.1-μm x-y and 0.3-μm z guard was applied to exclude 
spots intersecting the edge of the image volume. Synaptic loci were 
identified using custom MATLAB scripts from Sauerbeck (36) to 
find the nearest neighbor based on the x-y-z centroid of the top 20% 
brightest puncta. A cutoff of 270 nm pre-to-postsynaptic separation 
was used to quantify synaptic loci for Figure 6 from the frequency 
distribution of pre-to-postsynaptic separations. Complement label-
ing of synaptic loci was performed with Imaris 9.3.1 software by 
creating a surface of C1q staining based on a threshold applied to all 
images and by counting the number of pre- and postsynaptic spots 
positive for this surface. Three images per mouse were obtained in 
the polymorphic layer of the piriform cortex for this analysis.
Quantification of confocal images for Iba1 and CD68 was per-
formed on a semiautomated platform using MATLAB and Imaris 
9.3.1 software to create surfaces of each stain based on a threshold 
applied to all images and colocalize Iba1 and CD68 surfaces to evalu-
ate the volume of CD68+ vesicles within Iba1+ cells. For quantification 
of the number of PSD-95 puncta engulfed in CD68+ phagolysosomes, 
the PSD-95 puncta previously detected were automatically counted 
within the CD68+ surface per microglia using Imaris 9.3.1 software. 
Three to 5 microglia were imaged for each mouse or subject.
Immunofluorescence of human tissue. Paraffin-embedded 8-μm 
sections were dewaxed in xylene for 6 minutes twice, followed 
by rehydration descending ethanol to water (100% [twice], 95%, 
90%, 70%, 30%, and 10% ethanol, followed by 100% water 
[twice]). For antigen retrieval, slides were incubated for 45 min-
utes in citrate buffer, pH 6. Slides were incubated in 0.1% Sudan 
black solution in 70% ethanol for 20 minutes to eliminate autoflu-
orescence. After PBS washes, sections were blocked in 10% normal 
donkey serum and 0.3% Triton X-100 for 1 hour and then placed 
in primary antibodies overnight at 4°C in blocking solution: CD68 
(mouse monoclonal, 1:100; DAKO, M0876), Iba1 (goat polyclon-
al, 1:500; Abcam, ab5076), and PSD-95 (rabbit polyclonal, 1:200, 
Thermo Fisher Scientific, 51-6900). The following day, sections 
were washed, placed in secondary antibodies for 2 hours (Thermo 
Fisher Scientific; 1:500), and then washed again 3 times for 20 min-
utes each and mounted. Mounting medium was prepared the day 
of use by mixing Tris-MWL 4-88 (Electron Microscopy Sciences, 
17977- 150) with AF300 (Electron Microscopy Sciences, 17977-25) 
at a 9:1 ratio followed by vortexing and bench-top centrifugation to 
remove bubbles. High-precision 1.5H coverglasses were used for all 
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lar shape and delineating double membrane (74).
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